The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction

Cytokine and Growth Factor Reviews

Volumn 24, Issue 2, 2013, Pages 115-121

  Adamopoulos, Iannis E ^a   Pflanz, Stefan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Arthritis; Interleukin 17; Interleukin 23; Interleukin 27; Osteoclasts

Indexed keywords

GLYCOPROTEIN GP 130; I KAPPA B ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN 35; INTERLEUKIN RECEPTOR; MEMBRANE RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; SCLEROPROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; VITRONECTIN;

ARTHRITIS; BINDING AFFINITY; BONE DEFECT; BONE DESTRUCTION; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL POPULATION; CYTOKINE PRODUCTION; HUMAN; IMMUNOPATHOGENESIS; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TH17 CELL;

ANIMALS; ARTHRITIS; BONE RESORPTION; HUMANS; INTERLEUKIN-17; OSTEOCLASTS; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

EID: 84875268816     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.10.001     Document Type: Short Survey

References (102)

1. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
2. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
3. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor {kappa}B (RANK) receptors. Journal of Experimental Medicine 1999, 190:1741-1754.
4. Fuller K., Owens J.M., Jagger C.J., Wilson A., Moss R., Chambers T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. Journal of Experimental Medicine 1993, 178:1733-1744.
5. Gillespie M. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Research & Therapy 2007, 9:103.
6. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998, 12:1260-1268.
7. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
8. Yanni G., Whelan A., Feighery C., Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Annals of the Rheumatic Diseases 1994, 53:39-44.
9. Adamopoulos I.E., Sabokbar A., Wordsworth B.P., Carr A., Ferguson D.J., Athanasou N.A. Synovial fluid macrophages are capable of osteoclast formation and resorption. The Journal of Pathology 2006, 208:35-43.
10. Li J., Sarosi I., Yan X.-Q., Morony S., Capparelli C., Tan H.-L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences United States of America 2000, 97:1566-1571.
11. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. Journal of Biological Chemistry 2000, 275:4858-4864.
12. Adamopoulos I.E., Bowman E.P. Immune regulation of bone loss by Th17 cells. Arthritis Research & Therapy 2008, 10:225.
13. Pflanz S., Cheung T.J., Rosales J., Kanzler R., Gilbert H., Hibbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002, 16:779-790.
14. Devergne O., Hummel M., Koeppen H., Le Beau M.M., Nathanson E.C., Kieff E., et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. Journal of Virology 1996, 70:1143-1153.
15. Wirtz S., Fantini B.C., Nieuwenhuis M.C., Tubbe E.E., Galle I.P.R., Schild H.-J., et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-κB activation. Journal of Immunology 2005, 174:2814-2824.
16. Liu J., Guan X., Ma X. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. Journal of Experimental Medicine 2007, 204:141-152.
17. Molle C., Nguyen M., Flamand V., Renneson J., Trottein F., De Wit D., et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. Journal of Immunology 2007, 178:7607-7615.
18. Pirhonen J., Julkunen S.J., Matikainen I.S. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. Journal of Leukocyte Biology 2007, 82:1185-1192.
19. Smits H.H., van Beelen A.J., Hessle C., Westland R., de Jong E., Soeteman E., et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. European Journal of Immunology 2004, 34:1371-1380.
20. Devergne O., Kieff B.M.E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:12041-12046.
21. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
22. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nature Immunology 2010, 11:1093-1101.
23. Liu F., He T.F., Liu Y.H. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. Clinical Immunology 2011, 139:1-5.
24. Seyerl M., Majdic K.S., Seipelt O., Jindra J., Schrauf C., Stöckl C.J. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. European Journal of Immunology 2010, 40:321-329.
25. Bardel E., Charlot-Rabiega L.F., Coulomb-L'Herminé P., Devergne A.O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. Journal of Immunology 2008, 181:6898-6905.
26. Crabé S.G.-G.A., Tormo A.J., Duluc D., Lissilaa R., Guilhot F. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. Journal of Immunology 2009, 183:7692-7702.
27. Stumhofer J.S., Quinn T.E., 3rd W.J., Hosken N., Spudy B., Goenka R. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 2010, 11:1119-1126.
28. Collison L.W., Delgoffe G.M., Guy C.S., Vignali K.M., Chaturvedi V., Fairweather D., et al. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 2012, 13:290-299.
29. Watford W.T., Bream H.B., Kanno J.H., Muul Y., O'Shea L.J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunological Reviews 2004, 202:139-156.
30. Oppmann B., Blom L.R., Timans B., Xu J.C., Hunte Y., Vega B., et al. Novel p19 protein engages IL-12p40 to form a cytokine IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
31. Parham C., Timans C.M., Vaisberg J., Travis E., Cheung M., Pflanz J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology 2002, 168:5699-5708.
32. Jones L.L., Chaturvedi V., Uyttenhove C., Van Snick J., Vignali D.A.A. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Molecular Immunology 2012, 51:234-244.
33. Pflanz S., Mattson H.L., Rosales J., Vaisberg R., Bazan E.J.F. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. Journal of Immunology 2004, 172:2225-2231.
34. Silver J.S.H.C. gp130 at the nexus of inflammation, autoimmunity, and cancer. Journal of Leukocyte Biology 2010, 88:1145-1156.
35. Sprecher C.A., Baumgartner G.F., Presnell J.W., Schrader S.R., Yamagiwa S.K.T. Cloning and characterization of a novel class I cytokine receptor. Biochemical and Biophysical Research Communications 1998, 246:82-90.
36. Scheller J., Hölscher S.B., Yoshimoto C., Rose-John T.S. No inhibition of IL-27 signaling by soluble gp130. Biochemical and Biophysical Research Communications 2005, 326:724-728.
37. Morishima N., Asakawa O.T., Kamiya M., Mizuguchi S., Yoshimoto J.T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. Journal of Immunology 2005, 175:1686-1693.
38. Mayer K.D., Mohrs K., Reiley W., Wittmer S., Kohlmeier J.E., Pearl J.E., et al. Cutting edge: T-bet and IL-27R are critical for in vivo IFN-gamma production by CD8 T cells during infection. Journal of Immunology 2008, 180:693-697.
39. Yoshimoto T., Morishima O.K., Kamiya N., Owaki S., Asakawa T.M. Induction of IgG2a class switching in B cells by IL-27. Journal of Immunology 2004, 173:2479-2485.
40. Larousserie F., Bardel C.P., Froger E., Kastelein J., Devergne R.A.O. Differential effects of IL-27 on human B cell subsets. Journal of Immunology 2006, 176:5890-5897.
41. Liu L., Shan W.S., Shao B., Sato L., Kawamura A., Li K., et al. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scandinavian Journal of Immunology 2008, 68:22-29.
42. Wirtz S., Galle T.I., Schild P.R., Birkenbach H.J., Blumberg M.R.S., Neurath M.F. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin. Journal of Experimental Medicine 2006, 27 203:1875-1881.
43. Holtrop M.E., King G.J. The ultrastructure of the osteoclast and its functional implications. Clinical Orthopaedics 1977, 177-196.
44. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcified Tissue International 1982, 34:285-290.
45. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B L, or S, is abundantly expressed in human osteoclasts. The Journal of Biological Chemistry 1996, 271:12511-12516.
46. Hattersley G., Chambers T.J. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinology 1989, 125:1606-1612.
47. Davies J., Warwick J., Totty N., Philp R., Helfrich M., Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. Journal of Cell Biology 1989, 109:1817-1826.
48. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
49. Takayanagi H. The role of NFAT in osteoclast formation. Annals of the New York Academy of Sciences 2007, 1116:227-237.
50. Horton M.A., Taylor M.L., Arnett T.R., Helfrich M.H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Experimental Cell Research 1991, 195:368-375.
51. Zaidi M., Troen B., Moonga B.S., Abe E., Cathepsin K. Osteoclastic resorption, and osteoporosis therapy. Journal of Bone and Mineral Research 2001, 16:1747-1749.
52. Blair H.C., Teitelbaum S.L., Ghiselli R., Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989, 245:855-857.
53. Salo J., Lehenkari P., Mulari M., Metsikko K., Vaananen H.K. Removal of osteoclast bone resorption products by transcytosis. Science 1997, 276:270-273.
54. Nesbitt S.A., Horton M.A. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997, 276:266-269.
55. Seita J., Asakawa M., Ooehara J., Takayanagi S.-I., Morita Y., Watanabe N., et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008, 111:1903-1912.
56. Kamiya S., Nakamura C., Fukawa T., Ono K., Ohwaki T., Yoshimoto T., et al. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. Journal of Bone and Mineral Metabolism 2007, 25:277-285.
57. Park J.-S., Jung Y.O., Oh H.-J., Park S.J., Heo Y.-J., Kang C.-M., et al. Interleukin-27 suppresses osteoclastogenesis via induction of interferon-γ. Immunology 2012, [Epub ahead of print]. 10.1111/j.1365-2567.2012.03622.x.
58. Furukawa M., Takaishi H., Takito J., Yoda M., Sakai S., Hikata T., et al. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. Journal of Immunology 2009, 183:2397-2406.
59. Kalliolias G.D., Triantafyllopoulou Z.B., Park-Min A., Ivashkiv K.H.L.B. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis and Rheumatism 2010, 62:402-413.
60. Lanier L.L., Wu C.B., Leong J., Phillips C.J.H. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998, 391:703-707.
61. Daws M.R., Lanier L.L., Seaman W.E., Ryan J.C. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. European Journal of Immunology 2001, 31:783-791.
62. Vivier E., Nunes J.A., Vely F. Natural killer cell signaling pathways. Science 2004, 306:1517-1519.
63. Zou W., Reeve J.L., Liu Y., Teitelbaum S.L., Ross F.P. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Molecular Cell 2008, 31:422-431.
64. Zou W., Zhu T., Craft C.S., Broekelmann T.J., Mecham R.P., Teitelbaum S.L. Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts. Journal of Cell Science 2010, 123:2955-2963.
65. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaji M., et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. The Journal of Clinical Investigation 2003, 111:323-332.
66. Joyce-Shaikh B., Bigler M.E., Chao C.C., Murphy E.E., Blumenschein W.M., Adamopoulos I.E., et al. Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. Journal of Experimental Medicine 2010, 207:579-589.
67. Adamopoulos I., Sabokbar A., Wordsworth B., Carr A., Ferguson D., Athanasou N. Synovial fluid macrophages are capable of osteoclast formation and resorption. The Journal of Pathology 2006, 208:35-43.
68. Nakamura I., Kadono Y., Takayanagi H., Jimi E., Miyazaki T., Oda H., et al. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex. Journal of Immunology 2002, 168:5103-5109.
69. Hibbert L., De Waal Malefyt P.S., Kastelein R.R.A. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. Journal of Interferon and Cytokine Research 2003, 23:513-522.
70. Lucas S., Li G.N., de Sauvage J.F.J. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15047-15052.
71. Hamano S., Miyazaki H.K., Ishii Y., Yamanaka K., Takeda A., et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003, 19:657-667.
72. Chen S., Shi H.D., Shen X., Gu N., Bao Y.C. The relationship between Th1/Th2-type cells and disease activity in patients with systemic lupus erythematosus. Chinese Medical Journal (England) 2000, 113:877-880.
73. Yoshida H., Senaldi H.S., Covey G., Faggioni T., Mu R., et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001, 15:569-578.
74. Villarino A., Lieberman H.L., Wilson L., Mak E., Yoshida T., Kastelein H., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
75. Artis D., Joyce J.L., Saris K., Villarino C., Hunter A., Scott C.A.P. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. Journal of Immunology 2004, 172:4672-4675.
76. Artis D., Villarino A., Silverman M., He W., Thornton E.M., Mu S., et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. Journal of Immunology 2004, 173:5626-5634.
77. Yamanaka A., Hamano S., Miyazaki Y., Ishii K., Takeda A., Mak T.W., et al. Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. Journal of Immunology 2004, 172:3590-3596.
78. Miyazaki Y., Inoue H., Matsumura M., Matsumoto K., Nakano T., Tsuda M., et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. Journal of Immunology 2005, 175:2401-2407.
79. Hölscher C., Rückerl H.A., Yoshimoto D., Yoshida T., Mak H., Saris T., et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. Journal of Immunology 2005, 174:3534-3544.
80. Robinson K., Pidgeon K.R., Shakib E.L., Patel S., Polson S.R.J. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008, 57:1375-1385.
81. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. Journal of Experimental Medicine 2006, 203:2673-2682.
82. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of Clinical Investigation 1999, 103:1345-1352.
83. Adamopoulos I.E., Chao C.C., Geissler R., Laface D., Blumenschein W., Iwakura Y., et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Research & Therapy 2010, 12:R29.
84. Tyagi A.M., Srivastava K., Mansoori M.N., Trivedi R., Chattopadhyay N., Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS One 2012, 7:e44552.
85. Yago T., Nanke Y., Ichikawa N., Kobashigawa T., Mogi M., Kamatani N., et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17. Journal of Cellular Biochemistry 2009, 108:947-955.
86. Batten M., Yi L.J., Kljavin S., Danilenko N.M., Lucas D.M., Lee S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nature Immunology 2006, 7:929-936.
87. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nature Immunology 2006, 7:937-945.
88. Diveu C., McGeachy M.J., Boniface K., Stumhofer J.S., Sathe M., Joyce-Shaikh B., et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. Journal of Immunology 2009, 182:5748-5756.
89. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature Immunology 2007, 8:1363-1371.
90. Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J., Das Sarma J., et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. Journal of Immunology 2007, 179:3268-3275.
91. Awasthi A., Peron C.Y., Bettelli J.P., Kamanaka E., Flavell M., Kuchroo R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nature Immunology 2007, 8:1380-1389.
92. Neufert C., Wirtz B.C., Fantini S., Weigmann M.C., Galle B., Neurath P.R.M.F. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. European Journal of Immunology 2007, 37:1809-1816.
93. Batten M., Li K.N., Walter J., de Sauvage M.J., Ghilardi F.J.N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. Journal of Immunology 2008, 180:2752-2756.
94. Kamiya S., Okumura M., Chiba Y., Fukawa T., Nakamura C., Nimura N., et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunology Letters 2011, 138:47-53.
95. Cox J.H., Ramamoorthi K.N., Diehl N., Batten L., Ghilardi M.N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. Journal of Experimental Medicine 2011, 208:115-123.
96. Wong C.K., Chen da P., Tam L.S., Li E.K., Yin Y.B., Lam C.W. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Research & Therapy 2010, 12:R129.
97. Niedbala W., Cai B., Wei X., Patakas A., Leung B.P., McInnes I.B., et al. Interleukin 27 attenuates collagen-induced arthritis. Annals of the Rheumatic Diseases 2008, 67:1474-1479.
98. Shahrara S., Huang Q., Mandelin A.M. Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Research & Therapy 2008, 10:R93.
99. Tanida S., Yoshitomi H., Ishikawa M., Kasahara T., Murata K., Shibuya H., et al. IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine 2011, 55:237-244.
100. Baek S.H., Lee S.G., Park Y.E., Kim G.T., Kim C.D., Park S.Y. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis. Inflammation Research 2012, 61:1339-1345.
101. Cao Y., Doodes P.D., Glant T.T., Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. Journal of Immunology 2008, 180:922-930.
102. Shibata S., Tada Y., Asano Y., Yanaba K., Sugaya M., Kadono T., et al. IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. Journal of Investigative Dermatology 2012, [Epub ahead of print]. 10.1038/jid.2012.313.